Literature DB >> 6436822

Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains.

S L Morrison, M J Johnson, L A Herzenberg, V T Oi.   

Abstract

We have created mouse-human antibody molecules of defined antigen-binding specificity by taking the variable region genes of a mouse antibody-producing myeloma cell line with known antigen-binding specificity and joining them to human immunoglobulin constant region genes using recombinant DNA techniques. Chimeric genes were constructed that utilized the rearranged and expressed antigen-binding variable region exons from the myeloma cell line S107, which produces an IgA (kappa) anti-phosphocholine antibody. The heavy chain variable region exon was joined to human IgG1 or IgG2 heavy chain constant region genes, and the light chain variable region exon from the same myeloma was joined to the human kappa light chain gene. These genes were transfected into mouse myeloma cell lines, generating transformed cells that produce chimeric mouse-human IgG (kappa) or IgG (kappa) anti-phosphocholine antibodies. The transformed cell lines remained tumorigenic in mice and the chimeric molecules were present in the ascitic fluids and sera of tumor-bearing mice.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6436822      PMCID: PMC392030          DOI: 10.1073/pnas.81.21.6851

Source DB:  PubMed          Journal:  Proc Natl Acad Sci U S A        ISSN: 0027-8424            Impact factor:   11.205


  16 in total

1.  High resolution two-dimensional electrophoresis of basic as well as acidic proteins.

Authors:  P Z O'Farrell; H M Goodman; P H O'Farrell
Journal:  Cell       Date:  1977-12       Impact factor: 41.582

2.  Localization of murine Ig-1b and Ig-1a (IgG 2a) allotypic determinants detected with monoclonal antibodies.

Authors:  V T Oi; L A Herzenberg
Journal:  Mol Immunol       Date:  1979-12       Impact factor: 4.407

3.  Response of cutaneous T cell lymphoma to therapy with hybridoma monoclonal antibody.

Authors:  R A Miller; R Levy
Journal:  Lancet       Date:  1981-08-01       Impact factor: 79.321

4.  SV40 DNA transfection of cells in suspension: analysis of efficiency of transcription and translation of T-antigen.

Authors:  G Chu; P A Sharp
Journal:  Gene       Date:  1981-03       Impact factor: 3.688

5.  An immunoglobulin promoter region is unaltered by DNA rearrangement and somatic mutation during B-cell development.

Authors:  C Clarke; J Berenson; J Goverman; P D Boyer; S Crews; G Siu; K Calame
Journal:  Nucleic Acids Res       Date:  1982-12-11       Impact factor: 16.971

6.  Expression of a bacterial gene in mammalian cells.

Authors:  R C Mulligan; P Berg
Journal:  Science       Date:  1980-09-19       Impact factor: 47.728

7.  Selection for animal cells that express the Escherichia coli gene coding for xanthine-guanine phosphoribosyltransferase.

Authors:  R C Mulligan; P Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1981-04       Impact factor: 11.205

8.  Immunoglobulin gene expression in transformed lymphoid cells.

Authors:  V T Oi; S L Morrison; L A Herzenberg; P Berg
Journal:  Proc Natl Acad Sci U S A       Date:  1983-02       Impact factor: 11.205

9.  Lymphocyte membrane IgG and secreted IgG are structurally and allotypically distinct.

Authors:  V T Oi; V M Bryan; L A Herzenberg; L A Herzenberg
Journal:  J Exp Med       Date:  1980-05-01       Impact factor: 14.307

10.  Nucleic acid and protein sequences of phosphocholine-binding light chains.

Authors:  S P Kwan; S Rudikoff; J G Seidman; P Leder; M D Scharff
Journal:  J Exp Med       Date:  1981-05-01       Impact factor: 14.307

View more
  181 in total

1.  Rabbit monoclonal antibody: potential application in cancer therapy.

Authors:  Lifeng Feng; Xian Wang; Hongchuan Jin
Journal:  Am J Transl Res       Date:  2011-04-23       Impact factor: 4.060

Review 2.  Infectious disease therapy in the 1990s. Where are we heading?

Authors:  M Rozenberg-Arska; M R Visser
Journal:  Drugs       Date:  1992-05       Impact factor: 9.546

Review 3.  Recombinant antibodies for the diagnosis and treatment of cancer.

Authors:  Jürgen Krauss
Journal:  Mol Biotechnol       Date:  2003-09       Impact factor: 2.695

Review 4.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

Review 5.  Research and development of next generation of antibody-based therapeutics.

Authors:  Jing Li; Zhenping Zhu
Journal:  Acta Pharmacol Sin       Date:  2010-08-09       Impact factor: 6.150

Review 6.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 7.  Cancer nanomedicines: so many papers and so few drugs!

Authors:  Vincent J Venditto; Francis C Szoka
Journal:  Adv Drug Deliv Rev       Date:  2012-10-01       Impact factor: 15.470

Review 8.  Immunomodulation in the treatment of haematological malignancies.

Authors:  Michela Cesco-Gaspere; Emma Morris; Hans J Stauss
Journal:  Clin Exp Med       Date:  2009-02-24       Impact factor: 3.984

9.  A humanized antibody that binds to the interleukin 2 receptor.

Authors:  C Queen; W P Schneider; H E Selick; P W Payne; N F Landolfi; J F Duncan; N M Avdalovic; M Levitt; R P Junghans; T A Waldmann
Journal:  Proc Natl Acad Sci U S A       Date:  1989-12       Impact factor: 11.205

10.  A human/mouse chimeric monoclonal antibody against CA125 for radioimmunoimaging of ovarian cancer.

Authors:  H Kobayashi; H Sakahara; T Saga; M Hosono; M Shirato; H Kanda; K Ishibashi; T Watanabe; K Endo; I Ishiwata
Journal:  Cancer Immunol Immunother       Date:  1993-08       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.